Clinical Trial Update: Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations [Phase 3]

View source ↗

Summary

A Phase 3 trial compares almonertinib to placebo as adjuvant therapy after surgical resection in stage II-IIIB non-small cell lung cancer with EGFR-sensitizing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING